Scarica l'app Stockscreener
9.14
2.45%
-0.23
Dopo l'orario di chiusura:
9.05
-0.09
-0.98%
Sagimet Biosciences Inc Borsa (SGMT) Ultime notizie
Sagimet closes $115 million stock offering for drug development By Investing.com - Investing.com Canada
Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants - GlobeNewswire
Cantor Fitzgerald reiterates Sagimet stock rating on acne trial data By Investing.com - Investing.com Canada
Citizens cuts Sagimet Biosciences stock price target on trial data - Investing.com
Clear Street Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Oppenheimer raises Sagimet stock price target on acne trial data - Investing.com
Why is Sagimet Biosciences stock rallying today? By Investing.com - Investing.com Canada
Why Is Sagimet Biosciences Stock Trading Higher Today?Sagimet Biosciences (NASDAQ:SGMT) - Benzinga
Sagimet Biosciences Shares Rise 12% After Denifanstat Phase 3 Acne Trial Data - Yahoo Finance
Sagimet stock surges on positive acne trial data - Investing.com
Stock sales through Leerink are suspended at Sagimet Biosciences (SGMT). - Stock Titan
Sagimet Raises $115M At Premium To Fund Phase 3 Acne Drug Trial – SGMT Stock Surges Pre-Market - Yahoo Finance
Sagimet Reports 52-Week Denifanstat Acne Trial Results - grafa.com
Sagimet Prices $115 Million Offering of Series A Shares, Warrants; Shares Rise Pre-Bell - Yahoo Finance
Sagimet reports 52-week acne trial data, plans U.S. study - Investing.com
Sagimet prices $115 million stock offering at $10 per share By Investing.com - Investing.com South Africa
Sagimet prices $115 million stock offering at $10 per share - Investing.com
Sagimet reports 52-week acne drug trial results, plans U.S. study - Investing.com
Sagimet Biosciences details 56.7% acne response at 52 weeks - Mugglehead Investment Magazine
Sagimet Biosciences stock rises after pricing $115M securities offering - TradingView
About $115 million from a share sale is expected to help fund Sagimet's acne trial and other drug work. - Stock Titan
SGMT: Denifanstat achieved strong 52-week efficacy and safety, supporting advancement to U.S. Phase 3 trials - TradingView
A 240-patient open-label acne extension yields 52-week results for Sagimet (SGMT). - Stock Titan
Sagimet Biosciences Reports Positive 52-Week Phase 3 OLE Results for Denifanstat in Moderate to Severe Acne - Quiver Quantitative
Sagimet raised about $115 million, with an acne drug trial among its planned uses. - Stock Titan
Sagimet Biosciences Raises $115 Million in Stock Offering - Intellectia AI
Acne Vulgaris Market Set for Significant Growth During the Forecast Period (2026–2036), Amid Rising Disease Burden and Therapeutic Advances | DelveInsight - GlobeNewswire Inc.
H.C. Wainwright reiterates Sagimet stock rating on EADV data By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Sagimet stock rating on EADV data - Investing.com India
Sagimet to host event on denifanstat acne trial data Wednesday By Investing.com - Investing.com Nigeria
Sagimet to host event on denifanstat acne trial data Wednesday - Investing.com
Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat - GlobeNewswire
Sagimet Biosciences (SGMT): Phase 3 Trial, FDA Path and Cash Runway Set Up Key Catalysts - Insider Monkey
Sagimet Biosciences Down Over 15%, on Pace for Largest Percent Decrease Since April 2025 -- Data Talk - Moomoo
United Therapeutics, Sagimet drop after Goldman Sachs Sell ratings - TradingView
Sagimet Biosciences (SGMT) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Sagimet Biosciences Inc. (SGMT) Options ChainYahoo Finance - Yahoo! Finance Canada
SGMT Stock Surged 40% And Breached 200-DMA For The First Time In Nearly 3 Months – What’s Got Retail Buzzing? - Stocktwits
Barclays upgrades Sagimet stock rating on acne drug potential By Investing.com - Investing.com Nigeria
Sagimet Biosciences at Cantor conference: acne drug push gains traction By Investing.com - Investing.com Canada
This Illumina Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
symbol__ Stock Quote Price and Forecast - CNN
Barclays Upgrades Sagimet Biosciences to Overweight From Equalweight, Adjusts Price Target to $18 From $8 - marketscreener.com
Barclays upgrades Sagimet stock rating on acne drug potential - investing.com
A drug developer's investor chat is set for Sept. 9 in New York - Stock Titan
Enterprise value to EBIT forward of Sagimet Biosciences Inc.Series A – NASDAQ:SGMT - TradingView
H.C. Wainwright Maintains Sagimet Biosciences(SGMT.US) With Buy Rating, Maintains Target Price $29 - Moomoo
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial Of Denifanstat In Acne Toward Patient Enrollment In Q4 2026 - TradingView
Sagimet plans to start acne drug trial enrollment in Q4 - Investing.com India
Sagimet plans to start acne drug trial enrollment in Q4 By Investing.com - Investing.com Canada
Sagimet (SGMT) Earnings Report: Profit Per Share Clears Its Benchmark in Latest Trading - vinanet.vn
Balyasny Asset Management L.P. Acquires Stake in Sagimet Bioscie - GuruFocus
Sagimet Biosciences Inc. Series A Common Stock (NASDAQ: SGMT) Stock Price, News & Analysis - Kalkine
Sagimet Biosciences Director George Kemble Exercises Options and Sells 350,987 Shares - Kalkine Media
Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data - MarketBeat
Sagimet Biosciences (SGMT) Surges 13.7% to $10.55 as Biotech Momentum BuildsMFI Divergence - vinanet.vn
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):